cutaneous T-cell lymphoma

July 28, 2016July 28, 2016

Cutaneous T-Cell Lymphoma May Respond Longer to Different Romidepsin Dose Regimen

News

Patients with cutaneous T-cell lymphoma (CTCL) who are treated with romidepsin may have longer response periods with every other week dosing, or even once per month dosing, than with the standard dosing ... Read more

March 31, 2016March 31, 2016

Study of Cutaneous T-cell Lymphoma Genomics Likely to Lead to Targeted Therapies Soon, Expert Says

News

Booming knowledge of how genomics contributes to cutaneous T-cell lymphoma is likely to lead the way to new, targeted treatments for this type of cancer in the near future, according to Pierluigi ... Read more

March 3, 2016March 3, 2016

Cutaneous T-cell Lymphoma Phase 1 Clinical Trial of MiR-155 Inhibitor Now Enrolling Patients

News

miRagen Therapeutics, Inc., announced that it has started a Phase 1 clinical trial (NCT02580552) of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155. The trial’s primary ... Read more

November 11, 2015November 11, 2015

Sézary Syndrome Patients’ Genome IDs Mutations that Might Lead to Treatments

News

Genomic profiling analysis of Sézary syndrome patients has revealed key mutations in genes essential to T-cell signaling and cell cycle regulation. The research paper from The Baylor College of Medicine ... Read more

November 11, 2015November 11, 2015

Positive Value of Immunosequencing for Diagnosis of Cutaneous T-Cell Lymphoma

News

Adaptive Biotechnologies has published a study demonstrating that their revolutionary immunosequencing platform, which utilizes next-generation sequencing and advanced bioinformatics to sensitively profile all T cells in a biological sample, provides a more ... Read more

August 12, 2015August 12, 2015

Topical Gel Effective For Patients With Skin T Cell Lymphoma

News

Results of a phase one clinical study conducted by a team of researchers from the Perelman School of Medicine at the University of Pennsylvania, indicate that an investigational topical drug, ... Read more

August 6, 2015August 6, 2015

European Commission Grants SGX301 Orphan Drug Designation for Cutaneous T-cell Lymphoma

News

Late-stage biopharmaceutical company, Soligenix, Inc., known for developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced the European Commission, based on the recommendation ... Read more